The week in pharma: action, reaction and insight – week to September 1, 2023

3 September 2023

By Barbara Obstoj-Cardwell. Editor

Last week saw US biotech major Amgen reach a settlement with the Federal Trade Commission (FTC) regarding competition issues with its $27.8 billon proposed acquisition of Horizon Therapeutics, with particular issues concerning the potential bundling of the latter’s Krystexxa and Tepezza products. BridgeBio Pharma released new Phase III data on its acoramidis in ATTR cardiomyopathy at the European Society of Cardiology. On the deal-making front, ImmunoGen out-licensed its cancer treatment Elahere to Takeda for commercialization in Japan. The US Centers for Medicare and Medicaid (CMS) last Tuesday released the names of the first 10 drugs for price negotiations under the Inflation Reduction Act (IRA). Also of note, US biotech BioMarin Pharmaceuticals revealed it has treated a first patient with its gene therapy Roctavian for severe hemophilia A in Germany, marking the first commercial use in Europe.

Comments on Amgen/Horizon antitrust deal with FTC

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK